CN107922491B - 多价和多特异性结合dr5的融合蛋白 - Google Patents

多价和多特异性结合dr5的融合蛋白 Download PDF

Info

Publication number
CN107922491B
CN107922491B CN201680041274.2A CN201680041274A CN107922491B CN 107922491 B CN107922491 B CN 107922491B CN 201680041274 A CN201680041274 A CN 201680041274A CN 107922491 B CN107922491 B CN 107922491B
Authority
CN
China
Prior art keywords
gly
ser
ala
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680041274.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107922491A (zh
Inventor
J·C·蒂默
K·S·琼斯
A·S·拉扎伊
A·侯赛因
K·M·威利斯
Q·德沃拉克斯
B·P·艾克尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yinxibi Bioscience Co ltd
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Priority to CN202111039963.9A priority Critical patent/CN114106178A/zh
Publication of CN107922491A publication Critical patent/CN107922491A/zh
Application granted granted Critical
Publication of CN107922491B publication Critical patent/CN107922491B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201680041274.2A 2015-07-16 2016-07-18 多价和多特异性结合dr5的融合蛋白 Active CN107922491B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111039963.9A CN114106178A (zh) 2015-07-16 2016-07-18 多价和多特异性结合dr5的融合蛋白

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193309P 2015-07-16 2015-07-16
US62/193,309 2015-07-16
PCT/US2016/042862 WO2017011837A2 (en) 2015-07-16 2016-07-18 Multivalent and multispecific dr5-binding fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111039963.9A Division CN114106178A (zh) 2015-07-16 2016-07-18 多价和多特异性结合dr5的融合蛋白

Publications (2)

Publication Number Publication Date
CN107922491A CN107922491A (zh) 2018-04-17
CN107922491B true CN107922491B (zh) 2021-09-28

Family

ID=57757772

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680041274.2A Active CN107922491B (zh) 2015-07-16 2016-07-18 多价和多特异性结合dr5的融合蛋白
CN202111039963.9A Pending CN114106178A (zh) 2015-07-16 2016-07-18 多价和多特异性结合dr5的融合蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111039963.9A Pending CN114106178A (zh) 2015-07-16 2016-07-18 多价和多特异性结合dr5的融合蛋白

Country Status (25)

Country Link
US (4) US10308720B2 (https=)
EP (2) EP3798232A1 (https=)
JP (4) JP6807606B2 (https=)
KR (2) KR20250017305A (https=)
CN (2) CN107922491B (https=)
AU (3) AU2016291701B2 (https=)
CA (2) CA2991634C (https=)
CY (1) CY1123615T1 (https=)
DK (1) DK3322734T3 (https=)
ES (1) ES2833773T3 (https=)
HR (1) HRP20201785T1 (https=)
HU (1) HUE051896T2 (https=)
IL (3) IL292037A (https=)
LT (1) LT3322734T (https=)
MX (2) MX2018000523A (https=)
NZ (1) NZ777930A (https=)
PL (1) PL3322734T3 (https=)
PT (1) PT3322734T (https=)
RS (1) RS61062B1 (https=)
RU (2) RU2021111382A (https=)
SG (1) SG10201912410TA (https=)
SI (1) SI3322734T1 (https=)
SM (1) SMT202100066T1 (https=)
WO (1) WO2017011837A2 (https=)
ZA (1) ZA201800238B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN111819198A (zh) * 2017-12-28 2020-10-23 尤利乌斯·马克西米利安维尔茨堡大学 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA)
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
WO2020047705A1 (zh) * 2018-09-03 2020-03-12 安菲尼生命科技有限公司 Dr5单域抗体及其用途
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
BR112022006364A2 (pt) * 2019-10-01 2022-06-28 Epsilogen Ltd Anticorpo híbrido
CN115667316A (zh) * 2020-06-30 2023-01-31 和铂医药(上海)有限责任公司 Fab-HCAb结构的结合蛋白
JP7620780B2 (ja) * 2020-06-30 2025-01-24 ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質
US20230303698A1 (en) * 2020-06-30 2023-09-28 Harbour Biomed (Shanghai) Co., Ltd Multispecific binding protein of immune cell engager, preparation therefor and application thereof
IL305265A (en) * 2021-02-19 2023-10-01 Inhibrx Inc Preparations of DR5-binding polypeptides
AU2023248848A1 (en) * 2022-04-08 2024-10-17 Inhibrx Biosciences, Inc. Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy
TW202410919A (zh) * 2022-05-23 2024-03-16 美商英伊布里克斯公司 Dr5促效劑與iap拮抗劑之組合療法
CN117285644A (zh) * 2022-06-16 2023-12-26 清华大学 一种相变调节元件及其用途
JP2025534309A (ja) 2022-09-28 2025-10-15 ヴァリンク セラピューティクス リミテッド 多価タンパク質およびスクリーニング法
KR20260032566A (ko) * 2023-06-29 2026-03-09 오디세이 테라퓨틱스, 인코포레이티드 항-trailr2 항원-결합 단백질 및 그의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014623A (zh) * 2004-04-06 2007-08-08 健泰科生物技术公司 Dr5抗体及其用途
CN101717775A (zh) * 2009-11-13 2010-06-02 厦门大学 抗人死亡受体5的单链抗体基因
CN102884083A (zh) * 2010-02-10 2013-01-16 诺瓦提斯公司 Dr5 结合多肽激动剂
CN102924600A (zh) * 2012-11-14 2013-02-13 河南大学 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3298879B2 (ja) * 1990-12-20 2002-07-08 イグジス，インコーポレイテッド 結合タンパク質の最適化
US20020147140A1 (en) 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
CN101160524A (zh) 2005-02-24 2008-04-09 西米尼斯公司 用于生物样品分类的组合物和方法
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
AU2006323412A1 (en) 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
US8575070B2 (en) 2006-02-20 2013-11-05 Phylogica Limited Methods of constructing and screening libraries of peptide structures
JP2008133206A (ja) 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
BRPI0819598A2 (pt) 2007-11-30 2017-05-09 Kalobios Pharmaceuticals Inc anticorpos para o antígeno pcrv da pseudomonas aeruginosa
LT2285408T (lt) 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
EP2328929A2 (en) * 2008-09-10 2011-06-08 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
EP2408475B1 (en) 2009-03-18 2017-11-15 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
WO2010115141A2 (en) 2009-04-02 2010-10-07 New York University System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
EP3309176B1 (en) 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
EP2563816B1 (en) 2010-04-27 2014-11-12 National Research Council of Canada Anti-icam-1 single domain antibody and uses thereof
DK2621531T3 (en) * 2010-09-27 2017-02-27 Morphosys Ag ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
EP2632949B1 (en) 2010-10-25 2017-09-13 National Research Council of Canada Clostridium difficile-specific antibodies and uses thereof
MX2013007146A (es) 2010-12-23 2013-11-01 Intercell Austria Ag Agentes de proteina f/i de membrana externa (oprf/i) y su uso en pacientes hospitalizados y otros pacientes.
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
SMT202000091T1 (it) * 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
US9580509B2 (en) 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
EP2820043B1 (en) 2012-03-02 2020-01-15 Ablynx N.V. Biparatopic pseudomonas aeruginosa pcrv binding single variable domain antibodies
EP4151658A1 (en) 2012-05-07 2023-03-22 Elasmogen Limited Single domain binding molecule
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
WO2014043509A2 (en) 2012-09-13 2014-03-20 Novartis Ag Antigen binding molecule with terminal modifications
BR112015010240A2 (pt) 2012-11-06 2017-08-22 Medimmune Ltd Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
EP3004170A1 (en) 2013-05-28 2016-04-13 VIB vzw Single domain antibodies against sod1 and their use in medicine
KR20160103007A (ko) * 2014-01-10 2016-08-31 각코호진 데이쿄 헤이세이 다이가쿠 재조합 편성 혐기성 그램 양성균

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014623A (zh) * 2004-04-06 2007-08-08 健泰科生物技术公司 Dr5抗体及其用途
CN101717775A (zh) * 2009-11-13 2010-06-02 厦门大学 抗人死亡受体5的单链抗体基因
CN102884083A (zh) * 2010-02-10 2013-01-16 诺瓦提斯公司 Dr5 结合多肽激动剂
CN102924600A (zh) * 2012-11-14 2013-02-13 河南大学 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Kyriakos P. Papadopoulos等.Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor.《Cancer Chemother Pharmacol》.2015,第2015卷(第75期), *
Liposome-bound TRAIL induces superior DR5 clustering and andenhanced DISC recruitment in histiocytic lymphoma U937 cells;cellsDiego De Miguel等;《Leukemia Research》;20150404;第39卷(第6期);第657-666段 *
Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction;Heather A Huet等;《mAbs》;20141115;第6卷(第6期);第1561页左栏第2段 *

Also Published As

Publication number Publication date
HK1254433A1 (en) 2019-07-19
RU2018102803A3 (https=) 2019-12-27
AU2022291498A1 (en) 2023-02-02
IL256772A (en) 2018-03-29
SI3322734T1 (sl) 2021-02-26
HRP20201785T1 (hr) 2021-01-22
JP2025084923A (ja) 2025-06-03
HUE051896T2 (hu) 2021-03-29
MX2018000523A (es) 2018-04-13
LT3322734T (lt) 2021-02-10
BR112018000584A2 (pt) 2018-09-11
NZ738850A (en) 2024-11-29
US20170015753A1 (en) 2017-01-19
IL307994A (en) 2023-12-01
ZA201800238B (en) 2021-07-28
EP3798232A1 (en) 2021-03-31
JP2021046414A (ja) 2021-03-25
AU2026200317A1 (en) 2026-02-05
EP3322734B1 (en) 2020-09-09
CA3288875A1 (en) 2026-03-02
US20190309083A1 (en) 2019-10-10
AU2016291701A1 (en) 2018-01-25
IL292037A (en) 2022-06-01
ES2833773T3 (es) 2021-06-15
EP3322734A4 (en) 2019-04-17
IL256772B (en) 2022-05-01
JP2023022214A (ja) 2023-02-14
AU2016291701B2 (en) 2022-09-29
RS61062B1 (sr) 2020-12-31
WO2017011837A2 (en) 2017-01-19
NZ777930A (en) 2025-05-02
CA2991634C (en) 2026-03-17
KR102760380B1 (ko) 2025-01-31
US20220064318A1 (en) 2022-03-03
KR20250017305A (ko) 2025-02-04
SMT202100066T1 (it) 2021-03-15
JP6807606B2 (ja) 2021-01-06
CN107922491A (zh) 2018-04-17
US10308720B2 (en) 2019-06-04
PL3322734T3 (pl) 2021-05-04
WO2017011837A3 (en) 2017-03-02
US11117973B2 (en) 2021-09-14
MX2023002379A (es) 2023-03-21
JP7244938B2 (ja) 2023-03-23
US11976126B2 (en) 2024-05-07
CA2991634A1 (en) 2017-01-19
RU2021111382A (ru) 2021-05-21
KR20180030518A (ko) 2018-03-23
DK3322734T3 (da) 2020-10-26
RU2018102803A (ru) 2019-08-19
CN114106178A (zh) 2022-03-01
EP3322734A2 (en) 2018-05-23
JP2018522888A (ja) 2018-08-16
US20240376220A1 (en) 2024-11-14
RU2748620C2 (ru) 2021-05-28
SG10201912410TA (en) 2020-02-27
CY1123615T1 (el) 2022-03-24
PT3322734T (pt) 2020-11-30

Similar Documents

Publication Publication Date Title
CN107922491B (zh) 多价和多特异性结合dr5的融合蛋白
CN110305210B (zh) 新型抗体分子、其制备方法及其用途
US20200347143A1 (en) Novel tnfr agonists and uses thereof
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
WO2019184909A1 (zh) 新型抗体分子、其制备方法及其用途
TW202436358A (zh) Ｆａｐ／４－１ｂｂ／ｃｄ４０結合分子及其醫藥用途
HK40048814A (en) Multivalent and multispecific dr5-binding fusion proteins
HK1254433B (en) Multivalent and multispecific dr5-binding fusion proteins
WO2025185656A1 (zh) 抗pd-l1和cd40双特异性抗体及其用途
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
BR122025011160A2 (pt) Proteínas de fusão com ligação de dr5 multivalentes e multiespecíficas
BR112018000584B1 (pt) Polipeptídeo isolado que se liga pelo menos ao receptor de morte 5 (dr5) e seus usos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190201

Address after: California

Applicant after: INHIBRX L.P.

Address before: California, USA

Applicant before: Inhibrx, Inc.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240924

Address after: California, USA

Patentee after: Yinxibi Bioscience Co.,Ltd.

Country or region after: U.S.A.

Address before: California, USA

Patentee before: INHIBRX L.P.

Country or region before: U.S.A.